The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

RPEP-142022025Wu, Jianfeng; Pei, Fei; Zhou, Lixin; Li, Weiqin; Sun, Renhua; Li, Yimin; Wang, Zheng; He, Zhijie; Zhang, Xiaofei; Jin, Xiaodong; Long, Yun; Cui, Wei; Wang, Chunting; Chen, Erzhen; Zeng, Jun; Yan, Jing; Lin, Qinhan; Zhou, Feihu; Huang, Lei; Shang, You; Duan, Meili; Zheng, Wei; Zhu, Duming; Kou, Qiuye; Zhang, Shihong; Liu, Yin; Yao, Chen; Shang, Meixia; Peng, Sui; Zhou, Qian; Cheng, Kar Keung; Guan, Xiangdong

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

BMJ (Clinical research ed.), 388, e082583

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Jianfeng; Pei, Fei; Zhou, Lixin; Li, Weiqin; Sun, Renhua; Li, Yimin; Wang, Zheng; He, Zhijie; Zhang, Xiaofei; Jin, Xiaodong; Long, Yun; Cui, Wei; Wang, Chunting; Chen, Erzhen; Zeng, Jun; Yan, Jing; Lin, Qinhan; Zhou, Feihu; Huang, Lei; Shang, You; Duan, Meili; Zheng, Wei; Zhu, Duming; Kou, Qiuye; Zhang, Shihong; Liu, Yin; Yao, Chen; Shang, Meixia; Peng, Sui; Zhou, Qian; Cheng, Kar Keung; Guan, Xiangdong. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.. BMJ (Clinical research ed.), 388, e082583. https://doi.org/10.1136/bmj-2024-082583